On September 3, 2026, Hepion Pharmaceuticals entered into a convertible note purchase agreement with Gravitas Capital LP to issue a $500,000 secured convertible note. The note bears interest at 8% per annum, payable in kind, and matures on September 3, 2027. It is convertible at the option of Gravitas at a price of $0.04 per share, contingent upon stockholder approval to increase authorized common shares. Additionally, Hepion issued a warrant for 12,500,000 shares exercisable at $0.06 per share until September 3, 2031, also subject to the same stockholder approval condition. The note is secured by all of the company's assets under a separate security agreement. Hepion Pharmaceuticals operates in the biopharmaceutical industry.
